A cohort study of pediatric chronic kidney disease

A cohort study of pediatric chronic kidney disease - P-CKD cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015768

Enrollment

400

Registered

2014-11-28

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric pre-dialysis chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Predialysis patients with CKD in stage 3 or worse, based on the diagnostic criteria for CKD

Exclusion criteria

Exclusion criteria: History of dialysis or kidney transplantation

Design outcomes

Primary

Measure	Time frame
Initiation of dialysis or renal transplantation (with the date and details of procedure)	—

Secondary

Measure	Time frame
Annual examinations: 1) Physical examination with the measurement date: height, weight, and blood pressure 2) Use of growth hormones 3) Blood test with the measurement date: Hb, Ht, serum Cr (SCr), Alb, BUN, Na, K, Ca, IP, ferritin, Fe, TIBC, intact PTH, cystatin C, and blood gas 4) Urinalysis with the measurement date: protein (qualitative and semiquantitative) and Cr 5) Use of milk for CKD patient 6) Death: the date, cause, and detailed course of death Examinations for CAKUT (including neurogenic bladder) 1) Complicating congenital urinary tract abnormality 2) Obstructive uropathy (e.g. posterior urethral valves, ureteral cancer, hydronephrosis, hydroureter) 3) Bladder dysfunctions (including neurogenic bladder) 4) Date and process of detection (with height and SCr), date of surgery (with height and SCr), management procedure, and outcome of above 2) and 3) 5) Anal atresia Investigation of (perinatal) cortical necrosis 1) Characteristics of the mother: age, underlying disease, and prenatal medication 2) health status at birth: gestational age (weeks), parity , fetal complications, and Apgar score 3) Resuscitation 4) Complications within 14 days after birth including: pneumothorax, patent ductus arteriosus, pulmonary hypertension, gastrointestinal perforation, cerebral hemorrhage, subgaleal hematoma, periventricular leukomalacia, sepsis, oliguria, anuria 5) Interventions after birth (excluding medical therapy): ventilator, umbilical catheter, cardiac surgery, acute blood purification therapy, exchange transfusion 6) Medical therapy after birth 7) Minimum blood pressure value during neonatal period 8) Serum BUN and Cr: peak level within 14 days after birth	—

Measure

Time frame

Annual examinations: 1) Physical examination with the measurement date: height, weight, and blood pressure 2) Use of growth hormones 3) Blood test with the measurement date: Hb, Ht, serum Cr (SCr), Alb, BUN, Na, K, Ca, IP, ferritin, Fe, TIBC, intact PTH, cystatin C, and blood gas 4) Urinalysis with the measurement date: protein (qualitative and semiquantitative) and Cr 5) Use of milk for CKD patient 6) Death: the date, cause, and detailed course of death Examinations for CAKUT (including neurogenic bladder) 1) Complicating congenital urinary tract abnormality 2) Obstructive uropathy (e.g. posterior urethral valves, ureteral cancer, hydronephrosis, hydroureter) 3) Bladder dysfunctions (including neurogenic bladder) 4) Date and process of detection (with height and SCr), date of surgery (with height and SCr), management procedure, and outcome of above 2) and 3) 5) Anal atresia Investigation of (perinatal) cortical necrosis 1) Characteristics of the mother: age, underlying disease, and prenatal medication 2) health status at birth: gestational age (weeks), parity , fetal complications, and Apgar score 3) Resuscitation 4) Complications within 14 days after birth including: pneumothorax, patent ductus arteriosus, pulmonary hypertension, gastrointestinal perforation, cerebral hemorrhage, subgaleal hematoma, periventricular leukomalacia, sepsis, oliguria, anuria 5) Interventions after birth (excluding medical therapy): ventilator, umbilical catheter, cardiac surgery, acute blood purification therapy, exchange transfusion 6) Medical therapy after birth 7) Minimum blood pressure value during neonatal period 8) Serum BUN and Cr: peak level within 14 days after birth

—

Countries

Japan

Contacts

Public ContactYuko Hamasaki

Faculty of Medicine, Toho University Department of Nephrology

yuhamasaki@med.toho-u.ac.jp03-3762-4151

Outcome results